evinacumab
Indication: HoFH
Population PK simulator for evinacumab (Evkeeza), an ANGPTL3 inhibitor for homozygous familial hypercholesterolemia (HoFH). Two-compartment model with mixed linear and Michaelis-Menten elimination. Supports IV (15 mg/kg q4w) and SC dosing with allometric scaling.
Drug Overview
Clinical Context
- Molecular Target
- ANGPTL3
- Drug Class
- Monoclonal Antibody (ANGPTL3 Inhibitor)
- Therapeutic Area
- Cardiovascular / Lipid Disorders
- Indication
- HoFH
- Route of Administration
- IV, SC
Model Information
- Model Type
- 2-CMT mixed elimination
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for evinacumab allows you to explore concentration-time profiles under different dosing scenarios. The underlying 2-CMT mixed elimination model characterizes the pharmacokinetics of this monoclonal antibody (angptl3 inhibitor) following iv, sc administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the evinacumab PK simulator?
This is a free, interactive pharmacokinetic simulator for evinacumab used in HoFH. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does evinacumab belong to?
evinacumab is classified as a Monoclonal Antibody (ANGPTL3 Inhibitor) that targets ANGPTL3. It is used in the Cardiovascular / Lipid Disorders therapeutic area.
What route of administration does this model simulate?
This simulator models IV, SC administration of evinacumab. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a 2-CMT mixed elimination model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Ready to Simulate?
Launch the evinacumab simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community